

Rheumatology Association of Nevada



1st Annual Meeting
March 12, 2016

Mandalay Bay Resort & Casino
Las Vegas

PROGRAM BOOK



Greetings to all Nevada Rheumatology Providers,

The Rheumatology Association of Nevada (RAN) is a new organization offering a community to those who work in the field of rheumatology in Nevada. I am proud and delighted to be part of the founding of RAN in 2015, and serve as President of the organization.

The Rheumatology Association of Nevada is designed to bring together those in the field of rheumatology for conversations to improve quality of rheumatic care, increase awareness, and create a professional forum for scientific and advocacy issues that surround the field of rheumatology. For some time we have been working towards the formation of an association of rheumatologists and other rheumatology providers in Nevada. We have been assisted by WJ Weiser & Associates, a Chicago-based association management company that manages rheumatology advocacy groups in multiple states and also national groups. With their help we have reached a point of development that allows me to welcome you to the **RAN 1st Annual Meeting**, at the Mandalay Bay Resort & Casino in Las Vegas, Nevada.

This year's annual meeting features some of the top experts in their respective fields as speakers.

Thank you all for joining us this Saturday for what I envision to be a very interesting and productive meeting.

Sincerely,

Ewa Olech, MD
President, Rheumatology Association of Nevada

RAN 2016 BOARD OF DIRECTORS

President

Ewa Olech, MD

Vice President

George T. Kelly, MD

Secretary

Susan Knowles, MD

Treasurer

Christianne Yung, MD

Board Members

William Kim, MD

Program Committee

Ewa Olech, MD (Program Chair)

George T. Kelly, MD

Susan Knowles, MD

Christianne Yung, MD

Executive Director

Donna Rostamian, MBA



1st Annual Meeting March 12, 2016

Message from the President.....	1
Board of Directors	1
Educational Needs & Objectives	3
Accreditation.....	4
Faculty Disclosure Report	5
Program Schedule.....	7
General Meeting Information	8
Speaker Biographies	9
Thank You to Our 2016 Promotional Partners	Back Cover
Thank You to Our 2016 Exhibitors	Back Cover

Disclaimer Statement

Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of RAN nor does RAN provide any warranty as to their accuracy or reliability.

Copyright Notice

Individuals may print out single copies of abstracts or slides contained in this publication for personal, non-commercial use without obtaining permission from the author or RAN. Permission from both RAN and the author must be obtained when making multiple copies for personal or educational use, for reproduction for advertising or promotional purposes, for creating new collective works, for resale or for all other uses.

Filming/Photography Statement

No attendee/visitor at the RAN 1st Annual Meeting may record, film, tape, photograph, interview, or use any other such media during any presentation, display, or exhibit without the express, advance approval of the RAN Executive Director. This policy applies to all RAN members, non-members, guests, and exhibitors, as well as members of the print, online, or broadcast media.

Educational Needs:

Systemic Lupus Erythematosus is a chronic and unpredictable immune disorder which leads to organ damage and disability over time. Current standard of care is largely empiric, often ineffective and associated with significant adverse side effects. Technologic progress has made better treatment selection and more rational dosing feasible. Although clinical evolution of precision medicine for lupus remains rudimentary, it is timely to review recent advances and consider their wider application.

Interstitial lung disease (ILD) is recognized as a major cause of morbidity and mortality in patients with and without connective tissue disease. Over one hundred different forms of interstitial lung disease (ILD) have been described and are typically characterized by the presence of inflammation and altered lung interstitium. Specific forms of ILD can be differentiated from one another using clinical data, radiologic imaging and pathologic findings. Successful management of patients with ILD is dependent upon establishing an accurate diagnosis.

Imaging of inflammatory arthritis is of increasing importance in rheumatology clinical practice. The newer advanced imaging modalities are useful to obtain correct information of the degree of inflammation and disease activity, as well as to detect early destructive changes. The two imaging modalities emerging as the most promising are ultrasonography (US) and magnetic resonance imaging (MRI). They offer clinicians a chance to visualize not only joint damage, but also inflammatory changes and this information can be used for diagnosis, prognosis, as well as monitoring responses to therapy in routine clinical practice. Since imaging plays such an important role in managing patients with inflammatory arthritis, there is an unmet need to increase awareness and educate rheumatologists and other health care providers.

In today's health care world, there are many obstacles encountered while striving to run a successful rheumatology practice. Staffing effectiveness and efficiency, overhead increases, new revenue constraints, managed care contracting and compliance are just some of the pressures pushing practices to their limits. Thus, rheumatologists face important decisions regarding starting a private practice, and whether or not to accept insurance or practice concierge medicine, join another practice or a much larger health care organization or just calling it "quits".

A medical practice demands strategic economic knowledge where financial decisions can lead to a successful business or failure. Physicians need to be knowledgeable of the recent changes that have occurred and the future directions that rheumatologists will embrace to hopefully increase productivity, profitability, and overall patient and staff satisfaction.

Today's challenging health care environment is affecting the way physicians manage their practices, interfering with access to care and forcing them to make difficult decisions. Physicians seek to continue to provide quality care while contending with reduced Medicare reimbursement rates, medical claims, process errors and inefficiency, and legislative and regulatory changes. Rheumatologists need to be aware of emerging trends in practice management, payer reform, and administrative simplification of impact to the success of their practices and quality of patient care.

Educational Objectives:

At the conclusion of the Rheumatology Association of Nevada 1st Annual Meeting, attendees should be able to:

1. Review the role of chronic inflammation in progressive organ damage of SLE.
2. Review an update on the immunologic phenotypes of SLE patient subsets and evaluate the impact of these definable patient subsets on treatment choices and dose optimization.
3. Describe the clinical assessment of patients with Interstitial lung disease (ILD).
4. Describe the various treatments available for patients with ILD.
5. Recognize the indications for x-ray, MRI and US in patients with RA.
6. Review epidemiology, clinical features, diagnostic criteria and discuss radiographic findings in axial and peripheral seronegative SpA.
7. Recognize MRI and US features of SpA in:
 - Peripheral disease
 - SI joints
 - Spine
8. Review literature evaluating the use of imaging in lupus arthritis.
9. Explain the use of CT, scintigraphy and other imaging techniques in inflammatory arthritides.
10. Examine the business, legal and regulatory forces impacting the delivery of medical care, emphasizing the impact on rheumatology.
11. Explain practice settings: starting a practice, joining a practice or a larger health care organization.
12. Describe the utility and current financial environment of ancillary services.
13. Recognize that accountability and standards will inform payers and patients on how treatment decisions correlate to cost and quality.
14. Examine the business, legal and regulatory forces impacting the delivery of medical care, with a particular emphasis on the impact on rheumatology.

Accreditation

SAPS CME ACCREDITATION STATEMENT:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Southern Alliance for Physician Specialties and the Rheumatology Association of Nevada. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of **5.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE REPORT

Rheumatology Association of Nevada 1st Annual Meeting
 March 11 - 12, 2016
 Las Vegas, NV

In accordance with the ACCME Accreditation Criteria, the Southern Alliance for Physician Specialties (SAPS), as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a 'commercial interest' as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients". It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers "relevant" financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

PLANNING COMMITTEE/ CME ORGANIZERS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
KELLY, MD, George CME Organizer	Genetech	Consultant	Advisory Board
	Amgen	Consultant	Speaking Engagements
KNOWLES, MD, Susan CME Organizer	Eli Lilly	Consultant	Consultant
OLECH, MD, Ewa CME Organizer, Speaker	Nothing to disclose		
YUNG, MD, Christianne CME Organizer	Nothing to disclose		

SPEAKERS/ MODERATORS PANELISTS/ DISCUSSANTS/ CO-AUTHORS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
HARVEY, William Panelist	Nothing to disclose		
HERR, Krystin Panelist	Nothing to disclose		

Faculty Speaker Disclosures

RAN

SPEAKERS/ MODERATORS PANELISTS/ DISCUSSANTS/ CO-AUTHORS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
MERRILL, MD, Joan Speaker	Genetech/Roche	Grants/Research Support	PI
	UCB	Grants/Research Support	Speaker
	EMD Serono	Grants/Research Support	PI of registrational study
	BMS	Grants/Research Support	Investigator
	Medimmune	Grants/Research Support	Consultant
	Lilly	Grants/Research Support	Speaker
	Macrogenics	Consultant	Consultant
	Xencor	Grants/Research Support	PI of registrational study
	Questor, Celgene, Novo Nordisk, Seattle Genetics, Takeda, Macrogenics, Biogen- Idec, Neovacs, Anthera	Consultant	Consultant
	Pfizer, Exagen	Grants/Research Support	Contracted Research = PI
	Abbvie, Janssen	Consultant	Speaker
NORWICH, Julia Moderator	Nothing to disclose		
OLECH, MD, Ewa CME Organizer, Speaker	Nothing to disclose		
SCHWEITZ, MD, Michael Speaker, Panelist	Genetech	Other Financial or Material Support	Speaker's Bureau
TROUM, MD, Orrin Speaker	Abbvie, Amgen, BMS, Celgene, Centocor, Genetech, Pfizer	Consultant	Consultant
	AbbVie, Amgen, CORRONA, Pfizer	Grants/Research Support	Contracted Research
	Theralogiz	Stock Shareholder (directly purchased)	Owner Interest excluding diversified mutual funds
YOCUM, MD, David Speaker	Nothing to disclose		

All sessions will be located in **Tradewinds A** unless otherwise noted. Speakers and times are subject to change.

FRIDAY, MARCH 11, 2016

4:30 p.m. - 5:00 p.m.

Registration/Information Desk Open

Location: Mariner AB Foyer (North Convention Center)

5:00 p.m. - 5:30 p.m.

Industry Roundtable with Board Members

Location: Magellan Board Room

5:30 p.m. - 7:30 p.m.

Formational Founding Board Dinner

Location: Magellan Board Room

SATURDAY, MARCH 12, 2016

7:30 a.m. - 4:00 p.m.

Registration/Information Desk Open

Location: Mariner AB Foyer (North Convention Center)

8:00 a.m. - 3:00 p.m.

Exhibit Hall Open

Location: Mariner AB

8:00 a.m. - 9:00 a.m.

Industry Satellite Symposium Breakfast

Location: Tradewinds B

9:00 a.m. - 9:15 a.m.

Welcome

RAN President: Ewa Olech, MD
University of Nevada School of Medicine

9:15 a.m. - 10:00 a.m.

Systemic Lupus Erythematosus

Joan T. Merrill, MD
Oklahoma Medical Research Foundation

10:00 a.m. - 10:30 a.m.

Beverage Break and Networking Session in Exhibit Hall

10:30 a.m. - 11:15 a.m.

Interstitial Lung Disease in Autoimmune Disease

David E. Yocum, MD
Stanford University

11:15 a.m. - 12:00 p.m.

Imaging in Musculoskeletal Disease

Ewa Olech, MD
University of Nevada School of Medicine

12:00 p.m. - 1:15 p.m.

Networking Lunch with Exhibitors

Location: Mariner AB

1:15 p.m. - 1:45 p.m.

1st Annual Business/Formation Meeting

1:45 p.m. - 2:30 p.m.

The Future of Rheumatology

Orrin M. Troum, MD
USC Keck School of Medicine

2:30 p.m. - 3:00 p.m.

Beverage Break and Networking Session in Exhibit Hall

3:00 p.m. - 3:30 p.m.

Government Relations Update

Michael C. Schweitz, MD
CSRO, Federal Advocacy Chair

3:30 p.m. - 5:00 p.m.

Legislative and Advocacy Panel

Moderator: Julia Norwich
CSRO Associate Director

Michael Schweitz, MD
CSRO, Federal Advocacy Chair
William F. Harvey
American College of Rheumatology
Krystin Herr
Arthritis Foundation

5:00 p.m.

Adjourn

Registration/Information Desk Hours

Location: Mariner AB Foyer (North Convention Center)

Friday, March 11, 2016 4:30 p.m. – 5:00 p.m.

Saturday, March 12, 2016 7:30 a.m. – 4:00 p.m.

Exhibit Hall Hours

Location: Mariner AB

Saturday, March 12, 2016 8:00 a.m. – 3:00 p.m.

Industry Satellite Symposium

SATURDAY, MARCH 12, 2016

8:00 a.m. – 9:00 a.m.

***Industry Satellite Symposium Breakfast**

Location: Tradewinds B

“Applying Advanced IL 6 Treatment Strategies for Rheumatoid Arthritis”

CME presentation accredited through an outside provider: Academic CME

(CME documentation will be provided at the session)

William F. Harvey, MD

Dr. Harvey is a board certified rheumatologist practicing at Tufts Medical Center in Boston where he is the clinical director of the Arthritis Treatment Center. Dr. Harvey has of 20 years of healthcare advocacy experience and is the current Chair of the American College of Rheumatology Committee on Government Affairs.

Krystin Herr

Ms. Herr currently serves as the Arthritis Foundation, Pacific Region's Vice President of Government Affairs & Advocacy where she directs and implements both the public policy and grassroots advocacy agenda to ensure the residents of Arizona, California, Hawaii and Nevada living with arthritis are represented in their state legislature, state government health agencies, and statewide coalitions. Prior to joining the Arthritis Foundation, Ms. Herr served as the Legislative Consultant for the California Arthritis Foundation Council where she developed the Foundation's policy priorities

Joan T Merrill, MD

Dr. Merrill is the Head of the Clinical Pharmacology Research Program at the Oklahoma Medical Research Foundation, OMRF Professor of Medicine at the University of Oklahoma Health Sciences Center, and Medical Director of the Lupus Foundation of America. She is the Principal Investigator of the Oklahoma Lupus Cohort and has led numerous clinical trials of investigational agents in lupus. Her investigator-initiated studies have focused on developing novel protocols to help improve differentiation of treatments from placebo in lupus, and to improve pharmacodynamic understanding of immune modulating treatments and treatment interactions. She has authored more than 250 publications, including peer reviewed primary research papers, review articles, and book Chapters.

Julia A. Norwich

Julia Norwich is the Associate Director of the Coalition of State Rheumatology Organizations, whose mission is to promote state rheumatology society activities that advocate access to the highest quality medical care for rheumatic disease patients with autoimmune inflammatory and degenerative diseases. Julia has an educational and professional background in advocacy, including earning a Master's Degree in Public Policy and previously serving as a registered lobbyist for the National Association of Realtors (NAR).

Ewa Olech, MD

Dr. Olech is an associate professor of medicine and chief of rheumatology at the University of Nevada School of Medicine. Several of Dr. Olech's research projects focused on rheumatoid arthritis and evaluation of MRI as an outcome measure in clinical trials and in rheumatology practice. She has authored a number of publications on rheumatoid arthritis and musculoskeletal imaging, as well as presented on numerous occasions on these topics. Actively involved as a principal investigator in multiple clinical trials studying efficacy and safety of new therapies for the treatment of rheumatoid arthritis, Dr. Olech also has experience in conducting research studies in systemic lupus erythematosus, psoriatic arthritis, Sjogren's syndrome, osteoarthritis and osteoporosis.

Dr. Olech is one of the Founding Members of the International Society of Extremity MRI in Rheumatology, where she serves currently as Membership Secretary and Website Committee chair. She is also the President and Founding Member of the Rheumatology Association of Nevada and has recently been elected to serve on the Board of Directors panel of the Intersocietal Accreditation Commission MRI.

Michael C. Schweitz, MD

Dr. Schweitz is a partner in Arthritis and Rheumatology Associates of Palm Beach, an eight physician single specialty practice in Palm Beach County. He is fellow of the American College of Physicians and the American College of Rheumatology. He served as a member of the Committee on Rheumatologic Care. He is a past president of the Florida Society of Rheumatology and continues to sit on its Executive Committee. He is an active member of the American Society of Clinical Rheumatology.

Orrin M. Troum, MD, FACR

Dr. Troum is a clinical professor of medicine, Division of Rheumatology, at the Keck School of Medicine, University of Southern California (USC). Dr Troum attended the Autonomous University of Guadalajara and the College of Medicine and Dentistry of New Jersey prior to completing his internship/residency in internal medicine and fellowship in rheumatology at Los Angeles County/University of Southern California (LAC/USC) Medical Center. He is board certified in internal medicine and rheumatology. Dr. Troum is a founding fellow of the American College of Rheumatology, and a member of the Southern California Rheumatology Society (past president 1999-2000), California Rheumatology Alliance, Philadelphia Rheumatism Society, American Society of Bone and Mineral Research, Osteoarthritis and Research Society International and International Society of Clinical Densitometry.

David E. Yocum, MD

Dr. Yocum joined the faculty at the University Of Arizona College Of Medicine in 1986. He was Chief of the Section of Rheumatology from 1993 to 1995 and 1998 until 2004. He was also Director of the Arizona Arthritis Center from 1993 to 2004. In 2005, Dr. Yocum was recruited to the Genentech, Inc. in 2005 and has remained in biomedical pharmaceutical research. Since 2005, he has been an Adjunct Clinical Professor of Medicine at Stanford Medical Center and the Palo Alto VA Hospital. His primary research interests have been the development of immunomodulatory and biologic therapies as well as new treatments for fibrotic diseases in the rheumatic diseases.

Thank You to Our 2016 Promotional Partners

(as of 3/7/2016)

Silver Level Partners

AbbVie

Bristol-Myers Squibb

Celgene

Pfizer, Inc.

UCB, Inc.

Thank You to Our 2016 Exhibitors

(as of 3/7/2016)

AbbVie

Amgen

Antares Pharma

Bristol-Myers Squibb

Celgene

Crescendo Bioscience, Inc.

Ferring Pharmaceuticals

Genentech

GlaxoSmithKline

Horizon Pharma, Inc.

Janssen Biotech, Inc.

Mallinckrodt Pharmaceuticals

Medac Pharma, Inc.

Metro Medical

Novartis

Pfizer, Inc.

UCB, Inc.